Analyst Comment Chinese companies lead ADC pipeline ADCs are not a new technology, as there are currently 17 approved ADC drugs. GlobalData Healthcare
Analyst Comment Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Comment BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding
Analyst Comment Tymlos outperforms teriparatide in real-world fracture analysis GlobalData Healthcare
Analyst Comment The importance of AI in protecting hospitals from cyberattacks GlobalData Thematic Intelligence
Analyst Comment ACC 24: semaglutide lowers rates of heart failure hospitalisation GlobalData Healthcare
Analyst Comment MASH revival with over $2.5bn for innovator drug partnership deals in 2024 GlobalData Healthcare
Analyst Comment Measles cases continue to rise in US amid lagging vaccination rates GlobalData Healthcare
Analyst Comment Nanoscope Therapeutics exhibits positive top-line Phase IIb results for MCO-010 GlobalData Healthcare
Analyst Comment CRISPR drug licensing deals secure $21bn in top three therapy areas over five years GlobalData Healthcare
Analyst Comment Cheap drugs, inspections, and a future war in Europe – what’s driving drug shortages? GlobalData Healthcare
Analyst Comment Experts flag concerns with drug compliance in osteoporosis landscape GlobalData Healthcare
Analyst Comment CRISPR-based assay could revolutionise diagnosis of NTM infections GlobalData Healthcare
Analyst Comment IO360: first allogeneic dual CAR-T shows promise in B-cell Non-Hodgkin lymphoma GlobalData Healthcare
Analyst Comment IO360: Motixafortide shows Phase II efficacy in first-line pancreatic cancer GlobalData Healthcare
Analyst Comment PD-1 inhibitors and systemic oncolytic viral immunotherapies under the spotlight at IO360 GlobalData Healthcare
Analyst Comment BIOSECURE Act could impact WuXi-manufactured drugs for the US market GlobalData Healthcare
Analyst Comment Eli Lilly’s partnership with Amazon to boost presence in diabetes and obesity markets GlobalData Healthcare
Analyst Comment AD/PD 2024: BioVie’s novel NE3107 shows promise but confirmatory trial needed GlobalData Healthcare
Analyst Comment AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data GlobalData Healthcare
Analyst Comment Innovent’s ROS1 TKI is one step closer to winning the Chinese NSCLC market GlobalData Healthcare
Analyst Comment Oncology emerges as dominant therapy area for CRISPR technology GlobalData Healthcare